2018 American Transplant Congress
Opportunistic Infections after Kidney Transplantation Are Independent Risk Factor of Kidney Allograft Loss: A Retrospective Cohort Study
BackgroundCurrently, kidney allograft survival improved, use of depleting antibodies increased anddonor and recipient became older. In this context, no recent study reported epidemiology of opportunistic…2018 American Transplant Congress
The Effect of Steroid Maintenance in Recipients with Pancreas Transplant Alone: A Single Center Experience
Background: In solid organ transplantation, the use of steroids for maintenance therapy is common. However, the appropriateness of steroid maintenance or withdrawal in pancreas transplantation…2018 American Transplant Congress
Safety and Efficacy of Real-World Use of Everolimus for Kidney Transplant Patients: Post-Marketing Surveillance in Japan
Background and purpose: After the approval of everolimus (EVR) in 2011 in Japan to prevent organ rejection in kidney transplant (KTx) patients, no data on…2018 American Transplant Congress
Medicare Part D Plans Deny Coverage for Off-Label and Off-Compendia Immunosuppressant Use: A Case Series
Immunosuppressants are a protected drug class under the Medicare Part D benefit, meaning that all drugs in this class must be present on all plan…2018 American Transplant Congress
Steroid Avoidance in Renal Transplant Patients Treated with Everolimus and Low-Exposure Tacrolimus
Background: Previous studies reported efficacy and safety of steroid-free regimens after kidney transplant (KT). However, there is no robust evidence on this strategy in patients…2018 American Transplant Congress
Urinary CXCL9 Monitoring to Accompany a Safe CNI-to-Belatacept Conversion in Kidney Transplant Patients
Background: Converting renal transplant recipients from CNI to belatacept immunosuppression has been proposed as a strategy to limit nephrotoxicity, but it is associated with an…2018 American Transplant Congress
Long-Term Outcomes of Liver Transplantation in Patients with Pre-Transplant Renal Dysfunction Treated with Induction Therapy and Delayed Reduced De Novo Once-Daily Tacrolimus
AIM: To describe the long-term outcome of liver transplantation (LT) in patients with pre-transplant renal dysfunction treated with induction therapy and delayed reduced de novo…2018 American Transplant Congress
Analyzing Transplant Medication Myths
Division of Transplant, Virginia Mason Medical Center, Seattle, WA.
Patients may misconstrue the amount of medications required for transplantation, expecting to take “handfuls” of medications for life. This study aims to determine the change…2018 American Transplant Congress
Delayed Achievement of Therapeutic Tacrolimus Levels after Renal Transplantation is Not Associated with Increased Incidence of Early Acute Rejection: Single-Center Results
Division of Transplant Surgery, Department of Surgery, University of Washington, Seattle, WA.
Induction therapy followed by maintenance with a calcineurin inhibitor aims to minimize the incidence of early rejection and optimize the potential for allograft function. However…2017 American Transplant Congress
De Novo Low-Dose Sirolimus versus Mycophenolate Mofetil in Combination with Extended-Release Tacrolimus in Kidney Transplant Recipients.
Previous studies reported that tacrolimus (TAC) with high-dose sirolimus (SRL) was associated with worse outcomes in kidney transplantation, compared to TAC with mycophenolate mofetil (MMF.).…
- « Previous Page
- 1
- …
- 81
- 82
- 83
- 84
- 85
- …
- 138
- Next Page »